Presentation on theme: "In France By Thiébaut KELLER, Céline LEBLANC, Antoine LEPRETRE Best in France Case study September 2006 – December 2006."— Presentation transcript:
In France By Thiébaut KELLER, Céline LEBLANC, Antoine LEPRETRE Best in France Case study September 2006 – December 2006
Outlay Lilly’s overview Specific issues of the pharmaceutical sector Why and when did Lilly come to France Main constraints in France
Eli Lilly Co. Overview Eli Lilly & Co. Major drugs introduced
Eli Lilly & Co Founded in May 1876 by Colonel Eli Lilly in Indianapolis, USA 14.6 billion $ net sales in employees worldwide (19% in R&D) Clinical research in more than 50 countries Research and development facilities located in 9 countries Manufacturing plants located in 13 countries Products marketed in 143 countries : Lilly’s performance influences these economies Source (11/06 figures) : m/about/highlight s.html
Major drugs introduced (1/2) Prozac®, which revolutionized the treatment of depression Zyprexa®, breakthrough product for schizophrenia and acute mania associated with bipolar disorder Cialis®, a new treatment for erectile dysfunction Gemzar®, for pancreatic and non-small-cell lung cancer, one of the world's best-selling oncology agents Source : m/about/highlight s.html
Major drugs introduced (2/2) Humatrope®, therapy for growth hormone deficiency Humulin®, human insulin, the first human-health-care product created by biotechnology Ceclor®, which became the world's top- selling oral antibiotic Iletin®, the first commercially available insulin product, in 1923 Source : m/about/highlight s.html
Lilly France Overview Institut Lilly in France
Overview Headquarters in Suresnes (92 Hauts-de-Seine) Fegersheim’s plant (Alsace) : main production factory of the group’s subsidiaries, supplier of 126 countries all over the world. 2,02 billion € net sales (1,53 billion € from exports) 2980 employees : 4th most important subsidiary of Eli Lilly 10th best employer in Europe (Hewitt) 4 th “great place to work” in France in 2005
“Institut Lilly” in France Established in goals : –Supporting clinical research –Delivering educational and training programs to health care professionals and patients Has provided grants to 250 researchers Has delivered 90 training courses (90,000 professionals) –Specific courses for hospital pharmacists Ex: Aims at destigmatizing schizophrenia
Lilly’s values 3 main values Lilly’s values in France
3 main values Respect for people : –Employees, customers, shareholders, partners, suppliers and communities Integrity –Highest standards Search for excellence –Continuous search for ways to improve the performance Global values but adapted to each country to take into account cultural and corporate specificities.
Lilly’s values in France How do Lilly’s global values adapt to France? Example: Search for excellence: –Means being #1 in the USA –In France, it means excellence in methods and work quality. Being #2 doesn’t really conflicting with the search for excellence.
Specific issues of the pharmaceutical sector Clinical trials : specific and strict regulation Research and development Responsibility
Clinical trials : specific and strict regulation In France : “Autorisation de mise sur le marché”
Research and Development R&D expenses : –$2.7 billion –R&D development laboratories in 9 countries –Clinical research in 60 countries –20% of turnover invested in research Necessity to discover breakthrough products, thanks to medical expertise, in order to finance research for new drugs. Recruit and retain the highest quality employees is critical to success in this sector
Responsibility To act responsibly and consistently : –Observing and complying with the laws –Set standards in operations –Greater transparency on trials (www.lillytrials.com)www.lillytrials.com –Quality : people’s lives at stake : stakeholders trust is needed for the business to operate –Work with WHO –High standards in ethical behavior (social responsibility report) Health, safety and Environment program (3 points)
Why and when did Lilly come to France A strategic location Quality workforce A great market French health care system
A strategic location Plant in Alsace region: close to Germany, the first pharmaceutical market in the world At the center of Europe: –Infrastructures –Well served by transportation : roads, airport, train Close to European institutions Headquarters in Suresnes (92), near Paris: –Close to institutions and agencies (AFSSAPS, etc.) –Close to La Défense business district
A quality workforce Skilled and well-educated employees –Numerous students in pharmacy –Public research facilities: INSERM High productivity –Productivity higher in France than the productivity of other plants of the group Low absenteeism in Fegersheim France is a net-exporter of high-profile executives within the group
A great market France is a very attractive market : more than 19 billion € in 2001 US $2903 per capita vs. US $2307 in the OECD 340 doctors per inhabitants The French spend a lot of money on medicine : they rank second within the OECD.
French health care system Social security / High governmental investments 76.3% of health expenses paid by the government French doctors and hospitals are early adopters of new drugs In 2001, 38% of the turnover made with prescription drugs launched less than 10 years before vs. 26% in Germany Prices are not the lowest in Europe (close to the mean)
Main constraints in France Social forces and regulations Mentalities The Judiciary Administrative
Social forces and regulations 35h work week Everything needs to be negotiated : high risk of strike. HOWEVER Fegersheim’s plant is not syndicated. So far 0 day of strike.
Mentalities New employees are carefully selected to fit the corporate culture “Win-win” concept doesn’t always seem to be fully understood by the French –For example: new drugs will help the social and economic development of France and create value for Lilly –BUT it is sometimes only seen as a new cost for the Social Security
Judicial The French society has become very risk- adverse (risk of punitive damages) : –“ Principe de Précaution” is widely spread. Safety expectations are very high. –But in pharmaceuticals risk-zero does not exist Nevertheless, no class actions in France yet Difficulties for foreigners to understand the protection of unionists by Work Law.
Administrative Many governmental agencies with whom Lilly must continuously negotiate: AFSSAPS, etc. A lack of freedom to communicate about the products (whereas the lab knows its drugs the best) Sudden and unexpected political decisions (new taxes, etc.) in spite of annual contracts with firms. Very long approval process for new drugs : Usually 2 more years to get approval of new drugs (“Autorisation de mise sur le marché”) than in other countries
Perception of French issues by American chief executives Difficulties understanding both social and political phenomena But pragmatic approach : –Relative Autonomy of French staff –Everything is controlled and measured, including the mood of the workforce –Freedom as long as indicators remain as good as expected
Prospects Lilly keeps on investing in Fegersheim –Factory improvement and enlargement : Between 1998 and 2003, number of employees from 900 to 1800 : multiplied by 2.
Philippe DEFOSSES, Director of corporate affairs 13, rue Pagès Suresnes Cedex
« Lilly believes that strong economies [NDLR: like France!]with a priority on human health [NDLR: like France!] and educated population [NDLR: like the French!] will yield the ultimate health care solutions »